We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunomedics' Shares Surge YTD on Cancer Drug Approval
Read MoreHide Full Article
Share price of Immunomedics Inc. has surged 77.4% year to date compared with the industry’s growth of 11%. It has been an eventful year so far for the company.
The company got a significant boost in April 2020 with the FDA approval for its lead drug, Trodelvy, (sacituzumabgovitecan-hziy), an antibody-drug conjugate (ADC), for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who received at least two prior therapies for metastatic disease. Following the nod, Trodelvy became the first ADC to receive an FDA approval, specifically for the treatment of relapsed or refractory mTNBC, which is an aggressive type of breast cancer. It is also the first FDA-approved anti-Trop-2 ADC. This marks the approval of the first drug ofthe company and will boost its growth prospects. Shares got a boost with this approval.
The drug is also being evaluated for additional indications. The FDA recently granted a Fast Track designation to Trodelvy for the treatment of adult patients with locally-advanced or metastatic urothelial cancer (mUC).
Meanwhile, the ASCENT study on Trodelvy was halted due to compelling evidence of efficacy. The top-line data are expected around mid-2020.
Meanwhile, Immunomedics has collaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s (MRK - Free Report) anti-programmed cell death protein 1 (PD-1) antibody, Keytruda (pembrolizumab), in patients with mTNBC and hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC).
The company has also entered two clinical collaborations. It collaborated with Roche (RHHBY - Free Report) to develop Trodelvy in the front-line setting of mTNBC in combination with the latter’s PD-L1 inhibitor, Tecentriq.
The company has a similar collaboration agreement with AstraZeneca (AZN - Free Report) to investigate Trodelvy in combination with the latter’s checkpoint inhibitor, Imfinzi (durvalumab), in earlier lines of therapy for mTNBC, advanced UC and second-line metastatic NSCLC.
These collaborations are constant sources of funds for the company.
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Immunomedics' Shares Surge YTD on Cancer Drug Approval
Share price of Immunomedics Inc. has surged 77.4% year to date compared with the industry’s growth of 11%. It has been an eventful year so far for the company.
The company got a significant boost in April 2020 with the FDA approval for its lead drug, Trodelvy, (sacituzumabgovitecan-hziy), an antibody-drug conjugate (ADC), for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who received at least two prior therapies for metastatic disease. Following the nod, Trodelvy became the first ADC to receive an FDA approval, specifically for the treatment of relapsed or refractory mTNBC, which is an aggressive type of breast cancer. It is also the first FDA-approved anti-Trop-2 ADC. This marks the approval of the first drug ofthe company and will boost its growth prospects. Shares got a boost with this approval.
The drug is also being evaluated for additional indications. The FDA recently granted a Fast Track designation to Trodelvy for the treatment of adult patients with locally-advanced or metastatic urothelial cancer (mUC).
Meanwhile, the ASCENT study on Trodelvy was halted due to compelling evidence of efficacy. The top-line data are expected around mid-2020.
Meanwhile, Immunomedics has collaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s (MRK - Free Report) anti-programmed cell death protein 1 (PD-1) antibody, Keytruda (pembrolizumab), in patients with mTNBC and hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC).
The company has also entered two clinical collaborations. It collaborated with Roche (RHHBY - Free Report) to develop Trodelvy in the front-line setting of mTNBC in combination with the latter’s PD-L1 inhibitor, Tecentriq.
The company has a similar collaboration agreement with AstraZeneca (AZN - Free Report) to investigate Trodelvy in combination with the latter’s checkpoint inhibitor, Imfinzi (durvalumab), in earlier lines of therapy for mTNBC, advanced UC and second-line metastatic NSCLC.
These collaborations are constant sources of funds for the company.
Immunomedics, Inc. Price
Immunomedics, Inc. price | Immunomedics, Inc. Quote
Zacks Rank
Immunomedics is currently a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>